Last reviewed · How we verify
Antagon ™
Antagon is a gonadotropin-releasing hormone (GnRH) antagonist that rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to prevent premature ovulation during assisted reproductive technology.
Antagon is a gonadotropin-releasing hormone (GnRH) antagonist that rapidly suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to prevent premature ovulation during assisted reproductive technology. Used for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).
At a glance
| Generic name | Antagon ™ |
|---|---|
| Also known as | Ganirelix acetate |
| Sponsor | EMD Serono |
| Drug class | GnRH antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Antagon binds competitively to GnRH receptors on pituitary gonadotroph cells, causing immediate and reversible suppression of gonadotropin secretion. This prevents the endogenous LH surge that would otherwise trigger premature ovulation during controlled ovarian hyperstimulation in fertility treatment cycles.
Approved indications
- Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)
Common side effects
- Headache
- Ovarian hyperstimulation syndrome (OHSS)
- Abdominal pain
- Nausea
- Injection site reactions
Key clinical trials
- A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation (PHASE4)
- Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antagon ™ CI brief — competitive landscape report
- Antagon ™ updates RSS · CI watch RSS
- EMD Serono portfolio CI